Loading ...

Stock Quote 504398

504398 Stock Price Today

504398 Price History

504398 Stock Price History

504398 History

Last Price 504398

Close Price 504398

Day Change 504398

After Hours Quote 504398

Open Price 504398

Day Range 504398

Year Range 504398

Projected Yield 504398

Market Cap 504398

Stock Volume 504398

Average Volume 504398

Forward Price 504398

PE for 504398

PB for 504398

PS for 504398

PCF for 504398

price earnings ratio 504398

price to book ratio 504398

price to sales ratio 504398

price to cash flow ratio 504398

Stock Quote SJ Corp Ltd

SJ Corp Ltd Stock Price today

SJ Corp Ltd Price history

SJ Corp Ltd Stock Price history

SJ Corp Ltd history

Last Price SJ Corp Ltd

Close Price SJ Corp Ltd

Day Change SJ Corp Ltd

After Hours Quote for SJ Corp Ltd

Open Price SJ Corp Ltd

Day Range SJ Corp Ltd

Year Range SJ Corp Ltd

Projected Yield SJ Corp Ltd

Market Cap SJ Corp Ltd

Stock Volume SJ Corp Ltd

Average Volume SJ Corp Ltd

Forward Price SJ Corp Ltd

pe SJ Corp Ltd

pb SJ Corp Ltd

ps SJ Corp Ltd

pcf SJ Corp Ltd

price earnings ratio SJ Corp Ltd

price to book ratio SJ Corp Ltd

price to sales ratio SJ Corp Ltd

price to cash flow ratio SJ Corp Ltd

What Does This Company Do?
SJ Corp Ltd is engaged in manufacturing studded jewelry.
Sector
Consumer Cyclical
Industry
Luxury Goods
Stock Type
Employees
Stock Style
Small Growth

Key Stats  504398 More...

Key Stats 504398

S&P 500 index data: S&P 500 Copyright ©

All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .

News  504398 - SJ Corp Ltd More...

Seattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma at ASH Annual Meeting (2014/12/7)
Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS® (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting (2014/12/6)
Results from Phase III Study of REVLIMID® (Lenalidomide) Demonstrating Improved Transfusion Independence in Patients with Rare Blood Cancer, Non-Del-5Q Myelodysplastic Syndromes (MDS), Presented at ASH (2014/12/8)
Celgene Receives Positive CHMP Opinion to Extend REVLIMID® (Lenalidomide) for Continuous Use in Patients with Newly Diagnosed Multiple Myeloma and Ineligible for Transplant (2014/12/19)
Seattle Genetics and Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate Combination of Adcetris® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Hematologic Malignancies (2015/1/12)
Theravance Biopharma Enrolls First Patient in Phase 3 Registrational Study of Telavancin in Staphylococcus Aureus Bacteremia (2015/2/24)
ADDING MULTIMEDIA REVLIMID® (Lenalidomide) Approved by the European Commission for the Treatment of Adult Patients with Previously Untreated Multiple Myeloma who are Not Eligible for Transplant (2015/2/23)
ADDING MULTIMEDIA FDA Expands Indication for REVLIMID® (Lenalidomide) in Combination with Dexamethasone to Include Patients Newly Diagnosed with Multiple Myeloma (2015/2/19)
FDA Expands Indication for REVLIMID® (Lenalidomide) in Combination with Dexamethasone to Include Patients Newly Diagnosed with Multiple Myeloma (2015/2/18)
Seattle Genetics Submits Supplemental BLA to FDA for Phase 3 AETHERA Trial of ADCETRIS® (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at High Risk of Relapse (2015/2/18)
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days

Analysis  504398 - SJ Corp Ltd More...

Free Issue - Morningstar's Dividend Newsletter
More...

An investment is only as good as the cash it returns directly to your pockets. That's why Morningstar DividendInvestor's buy and sell recommendations are driven entirely by dividends. Our total-return strategy gives you carefully selected, picks that combine current income and income growth to generate large, reliable and growing cash returns. Click to try!

More reports 504398 - SJ Corp LtdMore...

Click above to view more mutual fund data and stats for 504398 - SJ Corp Ltd.

  • Performance
  • Asset Allocation
  • Dividend and Capital Gains Distribution
  • News, Alerts and Opinions
  • Video reports
  • Management
  • Filings

Wall St. Recommendations  504398 - SJ Corp Ltd More...

Wall Street Analyst Recommendation 504398

Stock Price Quote: 504398 SJ Corp Ltd - XBOM - Morningstar
Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry

Previous: 002028 - Siyuan Electric Co Ltd  |  Next: 3mg - SJM Holdings Ltd